HOOKIPA Pharma (HOOK) Announces Board of Directors Changes

HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.

“On behalf of the entire Board, I want to thank Jan for his more than seven years of loyal service and inspirational leadership of the Board of Directors and Tim for his insights and perspectives,” said Ms. O’Neill. “We understand their demanding schedules and are grateful for the years of service they provided HOOKIPA. I look forward to working with the management team on behalf of our shareholders and other stakeholders.”

Messrs. van de Winkel’s and Reilly’s board seats will remain unfilled, and the Board will comprise five members.

You May Also Be Interested In

• Jennifer Hyman to retire from Estee Lauder board in November
• Capstone Energy (CEPL) files mixed shelf
• Codexis (CDXS) files for 16.67M share offering by selling stockholders